{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:34:13Z","timestamp":1794249253977,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00896-w","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:02:28Z","timestamp":1736398948000},"page":"372-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4614-1266","authenticated-orcid":false,"given":"Tejas","family":"Jammihal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-597X","authenticated-orcid":false,"given":"Renee Maria","family":"Saliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-8455","authenticated-orcid":false,"given":"Chris","family":"Labaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Soulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9421-367X","authenticated-orcid":false,"given":"Juan","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnau","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"McCurry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valisha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-3543","authenticated-orcid":false,"given":"Deepak","family":"Poduval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-2396","authenticated-orcid":false,"given":"Talal","family":"El Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"El Ahmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-9843","authenticated-orcid":false,"given":"Yasmin Nabil","family":"Laimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseman Bagheri","family":"Sheshdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0657-9522","authenticated-orcid":false,"given":"Florian A.","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-075X","authenticated-orcid":false,"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-2287","authenticated-orcid":false,"given":"Rafael C.","family":"Casellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-6894","authenticated-orcid":false,"given":"Kunal","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki M.","family":"Zacharias Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-9591","authenticated-orcid":false,"given":"Jose","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9105","authenticated-orcid":false,"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-5553","authenticated-orcid":false,"given":"David A.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-3584","authenticated-orcid":false,"given":"Sachet A.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"896_CR1","unstructured":"Kidney and renal pelvis cancer\u2014cancer stat facts. National Cancer Institute Surveillance, Epidemiology and End Results Program https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html (2022)."},{"key":"896_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer, R. J., Bander, N. H. & Nanus, D. M.Renal-cell carcinoma. N. Engl. J. Med. 335, 865\u2013875 (1996).","journal-title":"N. Engl. J. Med."},{"key":"896_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges, L. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5, e001079 (2020).","journal-title":"ESMO Open"},{"key":"896_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133\u2013150 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"896_CR6","unstructured":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors. US Food and Drug Administration https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (2023)."},{"key":"896_CR7","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"896_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909\u2013918 (2020).","journal-title":"Nat. Med."},{"key":"896_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","volume":"359","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma HHS public access. Science 359, 801\u2013806 (2018).","journal-title":"Science"},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41591-018-0235-z","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Publisher correction: clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 1941 (2018).","journal-title":"Nat. Med."},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21068-9","volume":"12","author":"Z Bakouny","year":"2021","unstructured":"Bakouny, Z. et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat. Commun. 12, 1\u201314 (2021).","journal-title":"Nat. Commun."},{"key":"896_CR12","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","volume":"5","author":"DA Braun","year":"2019","unstructured":"Braun, D. A. et al. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol. 5, 1631 (2019).","journal-title":"JAMA Oncol."},{"key":"896_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","volume":"20","author":"M Rosellini","year":"2023","unstructured":"Rosellini, M. et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat. Rev. Urol. 20, 133\u2013157 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"896_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fonc.2019.00490","volume":"9","author":"I Heidegger","year":"2019","unstructured":"Heidegger, I., Pircher, A. & Pichler, R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front. Oncol. 9, 490 (2019).","journal-title":"Front. Oncol."},{"key":"896_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard, C. et al. Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br. J. Cancer 125, 927\u2013938 (2021).","journal-title":"Br. J. Cancer"},{"key":"896_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41568-019-0145-5","volume":"19","author":"FAM Saner","year":"2019","unstructured":"Saner, F. A. M. et al. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nat. Rev. Cancer 19, 339\u2013348 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"896_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert, C. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668\u20131674 (2018).","journal-title":"J. Clin. Oncol."},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell 37, 471 (2020).","journal-title":"Cancer Cell"},{"key":"896_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"896_CR20","doi-asserted-by":"publisher","first-page":"10051","DOI":"10.18632\/oncotarget.7067","volume":"7","author":"LGT Morris","year":"2016","unstructured":"Morris, L. G. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051\u201310063 (2016).","journal-title":"Oncotarget"},{"key":"896_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Saut\u00e8s-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"896_CR22","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"896_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 26, 487\u2013504 (2020).","journal-title":"Clin. Cancer Res."},{"key":"896_CR24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614 (2021).","journal-title":"Cell"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"e004316","DOI":"10.1136\/jitc-2021-004316","volume":"10","author":"RJ Motzer","year":"2022","unstructured":"Motzer, R. J. et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J. Immunother. Cancer 10, e004316 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541 (2022).","journal-title":"Immunity"},{"key":"896_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"896_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00262-021-03123-y","volume":"71","author":"W Xu","year":"2022","unstructured":"Xu, W. et al. Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. Cancer Immunol. Immunother. 71, 1923\u20131935 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"896_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01105-y","volume":"14","author":"FA B\u00fcttner","year":"2022","unstructured":"B\u00fcttner, F. A. et al. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Genome Med. 14, 105 (2022).","journal-title":"Genome Med."},{"key":"896_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.689076","volume":"12","author":"XL Zou","year":"2021","unstructured":"Zou, X. L. et al. Prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer. Front. Immunol. 12, 1\u20139 (2021).","journal-title":"Front. Immunol."},{"key":"896_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell 173, 595\u2013610 (2018).","journal-title":"Cell"},{"key":"896_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173, 581\u2013594 (2018).","journal-title":"Cell"},{"key":"896_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"896_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32, 377\u2013391 (2017).","journal-title":"Cancer Cell"},{"key":"896_CR35","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-18-0095","volume":"6","author":"PS Chowdhury","year":"2018","unstructured":"Chowdhury, P. S., Chamoto, K., Kumar, A. & Honjo, T. PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy. Cancer Immunol. Res. 6, 1375\u20131387 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"896_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang, W. et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature 531, 651\u2013655 (2016).","journal-title":"Nature"},{"key":"896_CR37","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel, S. et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162, 1242\u20131256 (2015).","journal-title":"Cell"},{"key":"896_CR38","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","volume":"117","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc. Natl Acad. Sci. USA 117, 6640\u20136650 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"896_CR39","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."},{"key":"896_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814\u2013824 (2019).","journal-title":"Nat. Med."},{"key":"896_CR41","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1002\/cncr.28151","volume":"119","author":"N Kroeger","year":"2013","unstructured":"Kroeger, N. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119, 2999\u20133006 (2013).","journal-title":"Cancer"},{"key":"896_CR42","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733\u20131741 (2020).","journal-title":"Nat. Med."},{"key":"896_CR43","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"896_CR44","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"896_CR45","doi-asserted-by":"publisher","unstructured":"Birger, C. et al. FireCloud, a scalable cloud-based platform for collaborative genome analysis: strategies for reducing and controlling costs. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/209494 (2017).","DOI":"10.1101\/209494"},{"key":"896_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"896_CR47","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/bioinformatics\/btr446","volume":"27","author":"K Cibulskis","year":"2011","unstructured":"Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601\u20132602 (2011).","journal-title":"Bioinformatics"},{"key":"896_CR48","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"896_CR49","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gks1443","volume":"41","author":"M Costello","year":"2013","unstructured":"Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).","journal-title":"Nucleic Acids Res."},{"key":"896_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","volume":"15","author":"A Taylor-Weiner","year":"2018","unstructured":"Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531\u2013534 (2018).","journal-title":"Nat. Methods"},{"key":"896_CR51","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714\u2013726 (2013).","journal-title":"Cell"},{"key":"896_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"896_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"896_CR54","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"896_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"896_CR56","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423\u2013E2429 (2015).","journal-title":"Hum. Mutat."},{"key":"896_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 173, 371\u2013385 (2018).","journal-title":"Cell."},{"key":"896_CR58","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"896_CR59","doi-asserted-by":"publisher","first-page":"113063","DOI":"10.1016\/j.celrep.2018.06.032","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 113063 (2018).","journal-title":"Cell Rep."},{"key":"896_CR60","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"896_CR61","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"896_CR62","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature11935","volume":"494","author":"RA Burrell","year":"2013","unstructured":"Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 494, 492\u2013496 (2013).","journal-title":"Nature."},{"key":"896_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16399-y","volume":"11","author":"CA Nichols","year":"2020","unstructured":"Nichols, C. A. et al. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat. Commun. 11, 1\u201314 (2020).","journal-title":"Nat. Commun."},{"key":"896_CR64","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"896_CR65","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","volume":"25","author":"D Chowell","year":"2019","unstructured":"Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 25, 1715\u20131720 (2019).","journal-title":"Nat. Med."},{"key":"896_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"896_CR67","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/bioinformatics\/btab135","volume":"37","author":"A Graubert","year":"2021","unstructured":"Graubert, A., Aguet, F., Ravi, A., Ardlie, K. G. & Getz, G. RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics 37, 3048\u20133050 (2021).","journal-title":"Bioinformatics"},{"key":"896_CR68","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"896_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"896_CR70","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular Signatures Database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"896_CR71","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"896_CR72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"896_CR73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"896_CR74","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A.Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243\u2013259 (2018).","journal-title":"Methods Mol. Biol."},{"key":"896_CR75","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"896_CR76","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"896_CR77","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","volume":"31","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol. 31, 1030\u20131039 (2020).","journal-title":"Ann. Oncol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00896-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T19:25:32Z","timestamp":1740597932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00896-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":77,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00896-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3088575\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. reports consulting and research funding from BMS, Ipsen, Novartis, Pfizer, Merck, Eisai and EMD Serono. P.M. reports honoraria for service on a scientific advisory board for Mirati Therapeutics, BMS and Exelixis, consulting for Axiom Healthcare Strategies, nonbranded educational programs supported by Exelixis and Pfizer and research funding for clinical trials from Takeda, BMS, Mirati Therapeutics, Gateway for Cancer Research and the University of Texas MD Anderson Cancer Center. S.S. reports commercial research grants from BMS, AstraZeneca, Exelixis and Novartis, is a consultant or advisory board member for Merck, AstraZeneca, BMS, CRISPR Therapeutics AG, AACR and NCI, receives royalties from Biogenex and mentors several non-US citizens on research projects with potential funding (in part) from non-US sources or foreign components. E.V.A. reports advisory or consulting roles for Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Riva Therapeutics and Serinus Bio, research support from Novartis, BMS and Sanofi, equity in Tango Therapeutics, Genome Medical, Genomic Life, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics and Serinus Bio, institutional patents filed on chromatin mutations and immunotherapy response and methods for clinical interpretation, intermittent legal consulting on patents for Foaley & Hoag and editorial board membership for JCO Precision Oncology and Science Advances. T.K.C. reports institutional and\/or personal, paid and\/or unpaid support for research, advisory boards, consultancy and\/or honoraria from Alkermes, AstraZeneca, Aravive, Aveo, Bayer, BMS, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date and CME events (Peerview, OncLive, MJH, CCO and others) outside the submitted work, institutional patents filed on molecular alterations and immunotherapy response\/toxicity and ctDNA, equity in Tempest, Pionyr, Osel, Precede Bio, CureResponse and InnDura, committee membership for NCCN, GU Steering Committee, ASCO\/ESMO, ACCRU and KidneyCan, potential medical writing and editorial assistance support funded by communications companies and mentorship of several non-US citizens on research projects with potential funding (in part) from non-US sources or foreign components. Dana-Farber Cancer Institute may have received additional independent funding from drug companies and\/or royalties potentially involved in research around the subject matter. D.A.B. reports honoraria from LM Education\/Exchange Services, advisory board fees from Exelixis and AVEO, consulting fees from Merck and Elephas, equity in Elephas, Fortress Biotech (subsidiary) and CurIOS Therapeutics, personal fees from Schlesinger Associates, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post\/Harborside, Targeted Oncology, AbbVie, Accolade 2nd.MD, DLA Piper and Merck and research support from Exelixis and AstraZeneca outside of the submitted work. S.A.S. has equity in Agenus, Agios Pharmaceuticals, Breakbio, BMS, Imunon, Jivanu Therapeutics and Lumos Pharma and receives consulting fees from Imunon and Jivanu Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}